Shares of Pfizer (NYSE:PFE) Sees Large Outflow of Money

Pfizer (NYSE:PFE) managed to stay afloat and traded higher with an addition of 0.25 point or 0.72% at $34.75. The money flow data is a negative $(-76.17) million with $91.31 million in upticks and $167.48 million in downticks. The intraday up/down ratio came in at 0.55. The shares have seen 1.55% change for the week in its share price.From the data available, it was found that a block transaction occurred during the course of trading. For it, the aggregated worth of the upticks was $8.3 million and the combined worth of the downticks was $92.15, Million, leading to the up/down ratio of 0.09. The block trade saw a net money flow of $(-83.85) million.


The stock has recorded a 20-day Moving Average of 0.18% and the 50-Day Moving Average is 3.43%.

Pfizer (NYSE:PFE): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $34.51 and $34.51 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $34.88. The buying momentum continued till the end and the stock did not give up its gains. It closed at $34.75, notching a gain of 0.72% for the day. The total traded volume was 25,356,674 . The stock had closed at $34.50 on the previous day.

Currently the company Insiders own 0.07% of Pfizer shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -18.54% . Institutional Investors own 75.07% of Pfizer shares. During last six month period, the net percent change held by insiders has seen a change of -18.54%. On the companys insider trading activities, The officer (Executive Vice President), of Pfizer Inc, Damelio Frank A had unloaded 100,000 shares at $34.49 per share in a transaction on May 26, 2016. The total value of transaction was $3,449,000. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.